Report
EUR 12.98 For Business Accounts Only

An unfavourable environment weighs on FATE THERAPEUTICS INCO., which sees a downgrade to Negative

The independent financial analyst theScreener just requalified the general evaluation of FATE THERAPEUTICS INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date January 11, 2022, the closing price was USD 47.54 and its target price was estimated at USD 35.90.
Underlying
Fate Therapeutics Inc

Fate Therapeutics is a biopharmaceutical company. The company's off-the-shelf, induced pluripotent stem cells (iPSC)-derived cellular immunotherapy pipeline include: FT500, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy for the treatment of solid tumors; and FT516, which is an off-the-shelf NK cell cancer immunotherapy. The company's other iPSC-derived cell product candidates include: FT301, an off-the-shelf, immuno-regulatory cell product candidate derived from a clonal master iPSC line. The company's allogeneic cellular immunotherapy pipeline include: ProTmune?, an investigational programmed cellular immunotherapy for use as an allogeneic hematopoietic cell transplantation cell graft.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch